Transgene’s Board of Directors Proposes the Appointment of Carol Stuckley, MBA, as New Independent Director
pharmafile | April 13, 2023 | Appointment | Business Services |
Strasbourg, France, April 12, 2023, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that the Board of Directors has proposed Ms. Carol Stuckley, MBA, as an independent Director of the Company. This appointment reflects the continued evolution of Transgene’s corporate governance, which takes into account director independence, gender diversity and relevant international business experience.
Ms. Carol Stuckley brings more than 35 years of experience as a strategic and international financial executive, with proven success leading finance teams and creating shareholder value for healthcare companies.
She currently serves as a Board Director and Chairperson of the audit committee of Centessa Pharmaceuticals, plc and previously served on the board of directors of Ipsen (where she chaired the audit committee) and Epizyme, Inc.
Ms. Carol Stuckley was formerly Chief Financial Officer and Senior Vice President at HPS, which was acquired by TransUnion, Inc. Previously, Carol was Chief Financial Officer, Vice President, Finance at Galderma North America (Nestlé Skin Health S.A.). Carol started her 23-year career at Pfizer Inc., where she held multiple financial roles of increasing responsibility, and was most recently Assistant Treasurer, Vice President, Finance and Corporate Officer of Pfizer Inc.
A US citizen, Carol holds a Master of Arts Degree in Economics and an MBA in International Finance from Temple University’s Fox Business School.
Ms. Carol Stuckley will replace Mrs. Laurence Espinasse, who resigned from her position as non-independent Director. Transgene’s shareholders will vote on the nomination of Carol Stuckley at the General Shareholder Meeting to be held on May 5, 2023.
Today, the Company published the related shareholder resolution in the BALO (Bulletin des Annonces Légales Obligatoires) n° 44 of April 12, 2023 a corrigendum to the notice of meeting equivalent to the notice of meeting initially published in the BALO (Bulletin des Annonces Légales Obligatoires) n° 35 of March 22, 2023.
Following the General Meeting, subject to the adoption of the proposed resolutions, Transgene’s Board of Directors will consist of 10 members, 6 of whom will be independent, benefiting from a wide range of skills relevant to the needs of the Company and respecting gender parity in accordance with the principles of French governance.
